Patent intelligence · CA
CA 3240096
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
Patent details — CA 3240096
- Jurisdiction
- CA
- Status
- granted
- Grant date
- May 19, 2023
- Expiration
- May 14, 2043
- Applicant
- NOVARTIS AG [CH]
- CPC classes
- A61K 51/ 08 A I, A61K/31282, A61K/31555, A61K/317048
Quick answer
CA 3240096 (POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON) is held by NOVARTIS AG [CH]. Status: granted. Granted May 19, 2023. Expires May 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- NOVARTIS AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 51/ 08 A I, A61K/31282, A61K/31555, A61K/317048, A61K/393955, A61K/4506
More from NOVARTIS AG [CH]
Related pharmaceutical patents in our USPTO index.
-
EP 4541380
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
granted -
CA 3235923
PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES
granted -
CA 3234495
POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES
granted -
CA 3215723
PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE
granted -
CA 3202908
ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted -
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted
Frequently asked questions
What is US patent 3240096?
CA 3240096 (POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON) is held by NOVARTIS AG [CH]. Status: granted. Granted May 19, 2023. Expires May 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3240096?
NOVARTIS AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3240096 expire?
Our index shows an expiration date of May 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.